文章：

外周血淋巴细胞/单核细胞绝对比值恢复在ABVD治疗周期预测经典霍奇金淋巴瘤的临床结局

Peripheral blood absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles predicts clinical outcomes in classical Hodgkin lymphoma

原文发布日期：2013-04-19

DOI: 10.1038/bcj.2013.8

类型: Original Article

开放获取: 是

英文摘要：

The peripheral blood absolute lymphocyte/monocyte count ratio at diagnosis (ALC/AMC-DX) predicts survival in classical Hodgkin lymphoma (cHL). However, a limitation of the ALC/AMC-DX is the inability to assess sequentially the host/tumor interaction during treatment. Therefore, we retrospectively examined the ALC/AMC ratio, as a surrogate marker of host immunity (ALC) and tumor microenvironment (AMC), at each adriamycin, bleomycin, vinblastine and dacarbazine treatment cycle as a predictor for clinical outcomes. From 1990 until 2008, 190 cHL patients were diagnosed, treated and followed at Mayo Clinic Rochester and qualified for the study. The ALC/AMC ratio at each treatment cycle was a predictor for overall survival (OS) and progression-free survival (PFS). An ALC/AMC ratio ⩾1.1 versus ALC/AMC <1.1 during treatment cycles was an independent predictor for OS (hazard ratio (HR)=0.14; 95% confidence interval (CI): 0.04–0.40; P<0.0002) and for PFS (HR=0.19; 95% CI: 0.05–0.82; P<0.03). The ALC/AMC ratio during treatment cycles is a predictor for survival and provides a platform to develop therapeutic modalities to manipulate the ALC/AMC ratio during chemotherapy to improve clinical outcomes in cHL.

摘要翻译： 

诊断时外周血绝对淋巴细胞/单核细胞比值（ALC/AMC-DX）可预测经典霍奇金淋巴瘤（cHL）的生存情况。然而ALC/AMC-DX的局限性在于无法连续评估治疗过程中宿主与肿瘤的相互作用。因此我们回顾性分析了每个ABVD（阿霉素、博来霉素、长春碱和达卡巴嗪）治疗周期中的ALC/AMC比值——作为宿主免疫力（ALC）和肿瘤微环境（AMC）的替代标志物——对临床结局的预测价值。1990年至2008年间，190例在梅奥诊所罗彻斯特院区确诊并接受随访治疗的cHL患者符合研究条件。每个治疗周期的ALC/AMC比值对总生存期（OS）和无进展生存期（PFS）具有预测价值。治疗周期中ALC/AMC比值⩾1.1相较于<1.1是OS（风险比=0.14；95%置信区间：0.04–0.40；P<0.0002）和PFS（风险比=0.19；95%置信区间：0.05–0.82；P<0.03）的独立预测因子。治疗期间的ALC/AMC比值可作为生存预测指标，并为开发通过调控化疗期间ALC/AMC比值来改善cHL临床结局的治疗方案提供平台。

原文链接：

Peripheral blood absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles predicts clinical outcomes in classical Hodgkin lymphoma